Drug Type Small molecule drug |
Synonyms JNJ 39393406 |
Target |
Action modulators |
Mechanism α7 receptor modulators(Neuronal acetylcholine receptor protein alpha-7 subunit modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
License Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC19H18F2N6O3 |
InChIKeyIURMHZBQEYNQOH-UHFFFAOYSA-N |
CAS Registry953428-73-4 |
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Depressive Disorder, Major | Phase 2 | United States | 01 Feb 2016 | |
| Depressive Disorder, Major | Phase 2 | Romania | 01 Feb 2016 | |
| Schizoaffective disorder | Phase 2 | United States | 01 Sep 2014 | |
| Schizophrenia | Phase 2 | United States | 01 Sep 2014 | |
| Smoking Cessation | Phase 2 | United States | 01 Sep 2014 | |
| Tobacco Use Disorder | Phase 2 | - | - | |
| Tobacco Use Disorder | Phase 2 | - | - | |
| Tobacco Use Disorder | Phase 2 | - | - | |
| Alzheimer Disease | Phase 1 | Germany | 01 Aug 2009 | |
| Cognition Disorders | Phase 1 | Germany | 01 Aug 2009 |
Phase 2 | 36 | placebo (Order 1--JNJ Active Then Plac) | tkyfvvcjvp(bhfrdnzhxg) = geevvgywfr hajttnuasq (bnzsvqtdgh, 1.3) View more | - | 15 Aug 2018 | ||
Placebo (Order 2--Placebo Then JNJ Active) | tkyfvvcjvp(bhfrdnzhxg) = dianvpqdxh hajttnuasq (bnzsvqtdgh, 0.6) View more | ||||||
Phase 2 | 62 | Placebo Pill+Active JNJ Drug (Active JNJ Drug) | didpbiubgg(wzifjghdnj) = ekrutwchiv sbnzhbgyqe (stemxreuja, 0.151) View more | - | 30 Jan 2018 | ||
Placebo Pill+Active JNJ Drug (Placebo Pill) | didpbiubgg(wzifjghdnj) = wcwvtlrddc sbnzhbgyqe (stemxreuja, 0.173) View more |





